Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes
2017-003619-20Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic retinopathy (DR) comparing Semaglutide + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Presence of 3 or more steps ETDRS subject level progression. Started Dec 2018; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2017-003619-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003619-20.